NEW YORK (GenomeWeb News) – Health Diagnostic Laboratory plans this summer to begin running studies of biomarkers comprising its Diabetes Prevention and Management Panel using clinical samples obtained in its purchase of assets from defunct diagnostics firm Tethys Bioscience.

HDL hopes the studies will provide data on the accuracy of its markers and panel for predicting patient conversion from a healthy state to pre-diabetes, as well as from pre-diabetes to diabetes and to more severe outcomes, Szilard Voros, the company's chief academic officer, told ProteoMonitor.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.